Evidence map›Paper›PMID 39660097›Full record

ArticleUrology case reports2025

Comprehensive genomic profiling of primary bladder mucinous adenocarcinoma, a rare genitourinary cancer: A case report.

Shinkuro Yamamoto, Shingo Ashida, Tomoya Nao, Kaho Murakami, Ryohei Iga, Tsutomu Shimamoto, Hideo Fukuhara, Nobutaka Shimizu, Satoshi Fukata, Atsushi Kurabayashi and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shinkuro YamamotoDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Shingo AshidaDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Tomoya NaoDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Kaho MurakamiJapanese Red Cross Kochi Hospital, Kochi, 780-8562, Japan.
Ryohei IgaDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Tsutomu ShimamotoDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Hideo FukuharaDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Nobutaka ShimizuPelvic Floor Center, Kochi Medical School, Nankoku, 783-8505, Japan.
Satoshi FukataPelvic Floor Center, Kochi Medical School, Nankoku, 783-8505, Japan.
Atsushi KurabayashiDepartment of Pathology, Kochi Medical School, Nankoku, 783-8505, Japan.
Takashi KarashimaDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.
Keiji InoueDepartment of Urology, Kochi Medical School, Nankoku, 783-8505, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary bladder mucinous adenocarcinoma is a rare genitourinary cancer. Here, we present the case of a 75-year-old woman where pathological and imaging findings led to the diagnosis of primary bladder mucinous adenocarcinoma. She underwent treatment with paclitaxel-ifosfamide-cisplatin (TIP). After two cycles of TIP therapy, FoundationOne CDx, a comprehensive genomic profiling test, was performed, revealing variants in

Indexed as

Bladder cancerGenomic profilingMucinous adenocarcinoma

Identifiers

PMID39660097
PMCPMC11629251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.